^
Association details:
| Biomarker: | PBRM1 mutation |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | FF-10502 (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors
Published date:
03/07/2023
Excerpt:
We conducted an open-label, single-arm, 3 + 3 first-in-human trial to explore the safety, tolerability, and antitumor activity of FF-10502-01 in patients with solid tumors….Prolonged progression-free survival in patients with cholangiocarcinoma was associated with BAP1 and PBRM1 mutations.
DOI:
10.1002/cncr.34709
